EL7.AI
StocksMedium•17 November 2026•
3 min read

Connect Biopharma Posts $16.2 Million Third-Quarter Net Loss

Key Facts

1The net loss was $16.2 million, or $0.26 per share, in the third quarter of 2026.
2Cash, cash equivalents and short-term investments totaled $19.5 million on September 30, 2026.
3The company expects its resources are unlikely to be sufficient to fund planned operations over the next 12 months.
4Rademikibart reduced the treatment failure rate 81% and new moderate-to-severe exacerbations 85% through week four in the chronic obstructive pulmonary disease study.

Connect Biopharma said on November 16, 2026, that it posted a net loss of $16.2 million, or $0.26 per share, in the third quarter, compared with a loss of $17.2 million and $0.31 per share in the same period of 2025. The company is developing rademikibart, an experimental drug being evaluated for asthma and chronic obstructive pulmonary disease. The results announcement was accompanied by updates on Phase 2 study results and plans to discuss potential Phase 3 programs with the U.S. Food and Drug Administration. Its quarterly report also showed that the company expects to need additional capital resources to fund its planned operations.

Cash, cash equivalents and short-term investments stood at $19.5 million on September 30, 2026, the company said. But its quarterly report said these resources are unlikely to be sufficient to fund planned operations over the next twelve months and that additional financing will be required. The company added that these conditions raise substantial doubt about its ability to continue as a going concern. Its accumulated deficit since inception was $453.7 million on September 30, 2026. It said it had not secured a recurring revenue source sufficient to cover operating costs, and that its ability to continue depends on obtaining adequate financing.

Research and development expenses rose to $12.8 million in the third quarter from $11.1 million in the same period of 2025. Connect attributed the increase mainly to rademikibart development costs, following the start of the Phase 2 asthma and chronic obstructive pulmonary disease studies in May 2025. In the chronic obstructive pulmonary disease study, the company said the treatment reduced the rate of treatment failure 81% through week four compared with placebo. It also reported an 85% reduction in new moderate-to-severe exacerbations over the same period. The company said both reductions were statistically significant, with p=0.0122 for treatment failure and p=0.0301 for exacerbations.

The company reported topline results in September from its Phase 2 asthma study, which included 160 patients randomized between rademikibart and placebo. Seventy-nine patients received treatment, compared with 81 in the placebo group. On day seven, post-bronchodilator forced expiratory volume in one second increased by 250 milliliters from baseline, compared with 120 milliliters with placebo. The company said the additional improvement of 130 milliliters was statistically significant, with a p-value of p=0.023. The treatment failure rate also fell by about 66% over 28 days compared with placebo, but the reduction was not statistically significant, with p=0.153.

Under its licensing agreement with Simcere for the development, manufacture and commercialization of rademikibart in Greater China, Connect said it is eligible for remaining milestone payments totaling up to about $99 million upon achievement of specified development, regulatory and commercial milestones. The agreement also provides for tiered royalties on net sales in the region reaching the low double digits, the company said. Connect plans to meet with the U.S. Food and Drug Administration in December 2026 to seek alignment on a potential Phase 3 program for acute asthma exacerbations. It is scheduled to discuss a potential Phase 3 program for chronic obstructive pulmonary disease in the first quarter of 2027. CNTB shares closed at $0.643 on November 16, according to EL7 data.

Open on chart